Elite Journal of Health Sciences. Volume 2 Issue 7(2024), Pp. 28-35
https://epjournals.com/journals/EJHS

Role of Myeloid-Derived Suppressor Cells in Vaso-Occlusive Crisis

*Emmanuel Ifeanyi Obeagu

Department of Medical Laboratory Science, Kampala International University, Uganda.

*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Vaso-occlusive crises (VOCs) are a hallmark complication of sickle cell disease (SCD), leading to acute pain and tissue ischemia due to the obstruction of small blood vessels by sickled red blood cells (RBCs). Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of immune cells that play a critical role in regulating immune responses and inflammation. Emerging evidence suggests that MDSCs significantly influence the pathophysiology of VOCs in SCD, contributing to the complex interplay between inflammation, immune modulation, and vascular dysfunction. MDSCs are known for their immunosuppressive properties, which can impair the activity of T cells and other immune cell types, resulting in a dysregulated immune response that exacerbates inflammation. In the context of SCD, the accumulation of MDSCs may promote an inflammatory microenvironment that enhances endothelial dysfunction and increases the risk of microvascular occlusion. Additionally, interactions between MDSCs, sickled RBCs, and endothelial cells may further contribute to the development of vaso-occlusive crises, highlighting the multifaceted role of these cells in the pathogenesis of SCD.

Keywords*: sickle cell disease, vaso-occlusive crisis, myeloid-derived suppressor cells, inflammation, immune regulation, therapeutic targets.*

Introduction

Sickle cell disease (SCD) is a hereditary hematological disorder caused by a mutation in the β-globin gene, resulting in the production of abnormal hemoglobin S (HbS). Under low oxygen conditions, HbS polymerizes, leading to the deformation of red blood cells (RBCs) into a characteristic sickle shape. These sickled RBCs have reduced deformability and increased adhesion to the endothelium, which predisposes individuals with SCD to vaso-occlusive crises (VOCs). VOCs are characterized by episodes of acute pain and tissue ischemia due to the obstruction of small blood vessels, significantly impacting the quality of life and increasing morbidity and mortality in affected individuals.[1-5] The pathophysiology of vaso-occlusive crises is multifaceted and involves a complex interplay of cellular and molecular mechanisms. Inflammation, oxidative stress, and endothelial dysfunction are key contributors to the development of VOCs. Inflammatory mediators released during sickling events promote the recruitment of leukocytes and exacerbate the adhesion of sickled RBCs to the vascular endothelium, leading to microvascular occlusion. Despite advancements in understanding the mechanisms underlying VOCs, effective management strategies remain limited, highlighting the need for further exploration of the cellular components involved in this process.[6-10] Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immune cells that play a critical role in regulating immune responses, particularly in the context of inflammation and cancer. MDSCs arise from myeloid progenitor cells and can be broadly classified into two main

subtypes: monocytic MDSCs (M-MDSCs) and granulocytic or polymorphonuclear MDSCs (PMN-MDSCs). These cells are characterized by their ability to suppress T cell activation and modulate immune responses through various mechanisms, including the production of immunosuppressive factors such as arginase-1, indoleamine 2,3-dioxygenase (IDO), and reactive oxygen species (ROS).[11-15]

Emerging evidence suggests that MDSCs may play a significant role in the pathogenesis of vaso-occlusive crises in SCD. The chronic inflammation associated with SCD can lead to the accumulation of MDSCs, which may further exacerbate the inflammatory environment and contribute to the dysregulation of immune responses. By influencing the activity of various immune cells, MDSCs can impact the overall immune balance and increase the risk of VOCs.[16-17] The relationship between MDSCs and VOCs is complex, as MDSCs not only participate in regulating inflammation but also interact with other components of the immune system. Their immunosuppressive properties can impair T cell responses, leading to a decreased ability to control inflammation and promote the clearance of sickled RBCs. Additionally, MDSCs can interact with endothelial cells, potentially contributing to endothelial dysfunction and increasing the likelihood of microvascular occlusion. This interplay between MDSCs, sickled RBCs, and endothelial cells underscores the need for further investigation into the mechanisms by which MDSCs contribute to the pathophysiology of vaso-occlusive crises.[18-22] In addition to their role in inflammation and immune modulation, MDSCs may also be involved in the pain pathways associated with vaso-occlusive crises. The release of inflammatory mediators from MDSCs can influence pain sensitivity and exacerbate the experience of pain during VOC episodes. Understanding the connections between MDSCs and pain mechanisms may provide new insights into managing pain in individuals with SCD, improving the overall treatment approach for VOCs. Given the significant role of MDSCs in the pathogenesis of vaso-occlusive crises, targeting these cells may present a novel therapeutic strategy for managing SCD. Interventions aimed at reducing MDSC accumulation, enhancing their functionality, or blocking their immunosuppressive effects could help restore immune balance and mitigate the inflammatory processes that contribute to VOCs. Additionally, therapies that focus on the interactions between MDSCs, sickled RBCs, and endothelial cells may improve vascular function and reduce the risk of vaso-occlusion.[23-29]

Mechanisms of Myeloid-Derived Suppressor Cells in Vaso-Occlusive Crisis

Myeloid-derived suppressor cells (MDSCs) play a critical role in regulating the inflammatory response associated with vaso-occlusive crises (VOCs) in sickle cell disease (SCD). During VOCs, the inflammatory environment is characterized by elevated levels of pro-inflammatory cytokines such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). MDSCs can be recruited to sites of inflammation, where they secrete these cytokines, amplifying the inflammatory response. This dysregulated inflammation contributes to further recruitment of immune cells, creating a feedback loop that perpetuates the inflammatory milieu and increases the risk of microvascular occlusion.[30-34] One of the hallmark features of MDSCs is their ability to suppress T cell activation and proliferation, which can significantly impact the immune response in SCD. MDSCs exert their immunosuppressive effects through various mechanisms, including the production of enzymes like arginase-1 and indoleamine 2,3-dioxygenase (IDO). Arginase-1 depletes arginine, an essential amino acid for T cell proliferation, while IDO catalyzes the degradation of tryptophan, leading to the inhibition of T cell function. The suppression of T cell responses can impair the ability of the

immune system to control inflammation and promote the clearance of sickled RBCs, further exacerbating the occurrence of vaso-occlusive crises.[35-39]

MDSCs can influence endothelial function, which is critical in the context of vaso-occlusive crises. Endothelial cells are responsible for maintaining vascular homeostasis, and their dysfunction is a key feature of SCD. MDSCs can interact with endothelial cells, leading to increased expression of adhesion molecules, such as P-selectin and E-selectin, which facilitate the adhesion of sickled RBCs and leukocytes to the endothelium. This interaction contributes to the obstruction of blood flow and the development of microvascular occlusions during VOCs. Furthermore, MDSCs may alter the production of vasodilatory factors, such as nitric oxide (NO), exacerbating endothelial dysfunction and promoting vaso-occlusive events.[40-44] MDSCs may also have direct interactions with sickled RBCs, further complicating the pathophysiology of vaso-occlusive crises. Sickled RBCs can release danger-associated molecular patterns (DAMPs) that stimulate MDSCs and activate their immunosuppressive pathways. This interaction can lead to increased MDSC accumulation and enhanced inflammatory responses, perpetuating a cycle that heightens the risk of vaso-occlusion. Additionally, the presence of sickled RBCs can alter MDSC function, potentially enhancing their ability to promote inflammation and suppress effective immune responses.[45-49]

Recent studies have suggested that MDSCs may play a role in the modulation of pain pathways associated with vaso-occlusive crises. The release of inflammatory mediators, such as cytokines and chemokines, from MDSCs can sensitize pain pathways and exacerbate the perception of pain during VOC episodes. MDSCs may interact with sensory neurons, influencing pain signaling and contributing to the acute pain characteristic of vaso-occlusive crises. MDSCs do not act in isolation; their functions are influenced by interactions with other immune cells in the microenvironment. For instance, MDSCs can promote the differentiation and expansion of T regulatory cells (Tregs), which further suppress the immune response. This crosstalk can create a microenvironment that favors chronic inflammation and impairs the ability to mount effective immune responses against the sickled RBCs. Additionally, MDSCs can interact with natural killer (NK) cells and dendritic cells, modulating their activity and influencing the overall immune landscape in SCD.[50-55] The presence of MDSCs can also affect the bone marrow microenvironment, where hematopoiesis occurs. MDSCs may influence the proliferation and differentiation of hematopoietic stem cells, impacting the production of RBCs and white blood cells. In SCD, where there is a chronic demand for RBC production due to hemolysis, the altered hematopoietic environment can contribute to ineffective erythropoiesis and exacerbate anemia. MDSCs are also known to contribute to oxidative stress, which plays a significant role in the pathophysiology of SCD. The activation of MDSCs during inflammatory responses can lead to the generation of reactive oxygen species (ROS), further exacerbating oxidative stress and endothelial dysfunction. Elevated oxidative stress levels can damage endothelial cells, promote the sickling of RBCs, and impair the ability of blood vessels to respond appropriately to physiological changes, thereby increasing the risk of vaso-occlusive crises.[56-62] Given the critical role of MDSCs in the pathogenesis of vaso-occlusive crises, targeting these cells presents a novel therapeutic opportunity for managing SCD. Strategies aimed at reducing MDSC accumulation, enhancing their functionality, or inhibiting their immunosuppressive effects may help restore immune balance and mitigate the inflammatory processes that contribute to VOCs. Additionally, therapies that focus on the interactions between MDSCs and other components of the immune system, such as

T cells and endothelial cells, may help improve vascular function and reduce the incidence of vaso-occlusion.[63-67]

Conclusion

Myeloid-derived suppressor cells (MDSCs) play a pivotal role in the pathophysiology of vaso-occlusive crises (VOCs) in sickle cell disease (SCD). Through their involvement in regulating inflammation, suppressing immune responses, and interacting with both sickled red blood cells and endothelial cells, MDSCs contribute significantly to the complex mechanisms underlying VOCs. Their ability to modulate inflammatory responses and influence endothelial dysfunction exacerbates the risk of microvascular occlusion, while their interactions with immune cells create an environment that favors chronic inflammation and pain. By exploring strategies to manipulate MDSC activity, researchers may develop innovative approaches to mitigate the impact of VOCs, ultimately improving patient outcomes and quality of life for individuals living with sickle cell disease.

References

1. Alenzi FQ, AlShaya DS. Biochemical and molecular analysis of the beta-globin gene on Saudi sickle cell anemia. Saudi Journal of Biological Sciences. 2019;26(7):1377-1384.
2. Williams TN, Thein SL. Sickle cell anemia and its phenotypes. Annual review of genomics and human genetics. 2018;19(1):113-147.
3. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
4. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
5. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
6. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
7. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
8. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-158.
9. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-2487.
10. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
11. Gkaliagkousi E, Ritter J, Ferro A. Platelet-derived nitric oxide signaling and regulation. Circulation research. 2007 Sep 28;101(7):654-662.
12. Tran N, Garcia T, Aniqa M, Ali S, Ally A, Nauli SM. Endothelial nitric oxide synthase (eNOS) and the cardiovascular system: in physiology and in disease states. American journal of biomedical science & research. 2022;15(2):153.
13. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-0487.

14. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.
15. Njar VE, Ogunnaya FU, Obeagu EI. Knowledge And Prevalence of The Sickle Cell Trait Among Undergraduate Students Of The University Of Calabar. Prevalence.;5(100):0-5.
16. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
17. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
18. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
19. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
20. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.
21. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
22. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
23. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
24. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
25. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology. 2024;2(3):67-80.
26. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).
27. Vilas-Boas W, Cerqueira BA, Zanette AM, Reis MG, Barral-Netto M, Goncalves MS. Arginase levels and their association with Th17-related cytokines, soluble adhesion molecules (sICAM-1 and sVCAM-1) and hemolysis markers among steady-state sickle cell anemia patients. Annals of hematology. 2010; 89:877-882.
28. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-265.
29. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
30. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.

31. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023; 6 (2): 10-13.
32. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
33. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
34. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
35. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
36. Tsikas D. Does the inhibitory action of asymmetric dimethylarginine (ADMA) on the endothelial nitric oxide synthase activity explain its importance in the cardiovascular system? The ADMA paradox. Journal of Controversies in Biomedical Research. 2017;3(1):16-22.
37. Martins R, Knapp S. Heme and hemolysis in innate immunity: adding insult to injury. Current opinion in immunology. 2018; 50:14-20.
38. Wu G, Meininger CJ, McNeal CJ, Bazer FW, Rhoads JM. Role of L-arginine in nitric oxide synthesis and health in humans. Amino acids in nutrition and health: Amino acids in gene expression, metabolic regulation, and exercising performance. 2021:167-87.
39. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
40. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michael okpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
41. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
42. Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:58-66.
43. Roberts BW, Mitchell J, Kilgannon JH, Chansky ME, Trzeciak S. Nitric oxide donor agents for the treatment of ischemia/reperfusion injury in human subjects: a systematic review. Shock. 2013;39(3):229-339.
44. Obeagu EI, Obeagu GU. Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sickle Cell Disease Education. Elite Journal of Health Science. 2024;2(2):7-15.
45. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine. 2024 Feb 9;103(6):e37127.

46. Obeagu EI. Chromium VI: A Silent Aggressor in Sickle Cell Anemia Pathophysiology. Elite Journal of Haematology, 2024; 2 (3).:81-95.
47. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
48. Samidurai A, Xi L, Das A, Kukreja RC. Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders. Annual review of pharmacology and toxicology. 2023;63(1):585-615.
49. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine. 2024;103(2):e36898.
50. Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science. 2024;2(2):1-9.
51. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.
52. Obeagu EI, Obeagu GU, Hauwa BA. Optimizing Maternal Health: Addressing Hemolysis in Pregnant Women with Sickle Cell Anemia. Journal home page: http://www. journalijiar. com.;12(01).
53. Obeagu EI, Obeagu GU. Synergistic Care Approaches: Integrating Diabetes and Sickle Cell Anemia Management. Elite Journal of Scientific Research and Review. 2024;2(1):51-64.
54. Grzywa TM, Sosnowska A, Matryba P, Rydzynska Z, Jasinski M, Nowis D, Golab J. Myeloid cell-derived arginase in cancer immune response. Frontiers in immunology. 2020; 11:938.
55. Obeagu EI, Obeagu GU. Improving Outcomes: Integrated Strategies for Diabetes and Sickle Cell Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2024;11(2):20-9.
56. Obeagu EI, Obeagu GU. The Role of Parents: Strengthening Adolescent Education for Sickle Cell Disease Prevention. Elite Journal of Public Health. 2024;2(1):15-21.
57. Obeagu EI, Obeagu GU. Hemolysis Challenges for Pregnant Women with Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:67-80.
58. Obeagu EI, Obeagu GU. Overcoming Hurdles: Anemia Management in Malaria-Affected Childhood. Elite Journal of Laboratory Medicine. 2024;2(1):59-69.
59. Bontempo P, Capasso L, De Masi L, Nebbioso A, Rigano D. Therapeutic Potential of Natural Compounds Acting through Epigenetic Mechanisms in Cardiovascular Diseases: Current Findings and Future Directions. Nutrients. 2024;16(15):2399.
60. Cao M, Zhao Y, He H, Yue R, Pan L, Hu H, Ren Y, Qin Q, Yi X, Yin T, Ma L. New applications of HBOC-201: a 25-year review of the literature. Frontiers in Medicine. 2021; 8:794561.
61. Brun M, Bourdoulous S, Couraud PO, Elion J, Krishnamoorthy R, Lapoumeroulie C. Hydroxyurea downregulates endothelin-1 gene expression and upregulates ICAM-1 gene expression in cultured human endothelial cells. The Pharmacogenomics Journal. 2003;3(4):215-226.
62. Obeagu EI. Redox Signaling and Vaso-Occlusive Crisis in Sickle Cell Anemia. *Elite Journal of Haematology, 2024; 2(7):* 26-35

63. Obeagu EI. Hypoxia-Induced Signaling in the Pathogenesis of Vaso-Occlusive Crisis. *Elite Journal of Haematology, 2024; 2(7):* 36-43
64. Obeagu EI. Neurovascular Regulation and Vaso-Occlusive Crisis in Sickle Cell Disease. Elite Journal of Medicine, 2024; 2(7): 41-48
65. Obeagu EI. Bone Marrow Microenvironment and Vaso-Occlusive Crisis in Sickle Cell Disease. Elite Journal of Medicine, 2024; 2(7): 49-56
66. Obeagu EI. Role of G6PD Deficiency in Vaso-Occlusive Phenomena in Sickle Cell Disease. Elite Journal of Medical Sciences, 2024; 2(7):49-57
67. Obeagu EI. Role of the Reticuloendothelial System in Sickle Cell Vaso-Occlusion. Elite Journal of Medical Sciences, 2024; 2(7):58-65